REGULATION OF LINEAGE CONVERSION THERAPIES IN MEDICINE

INTRODUCTION

Lineage conversion therapy involves transforming one differentiated cell type directly into another without necessarily passing through a pluripotent stem-cell stage. This process, also called direct reprogramming or transdifferentiation, has potential applications in regenerative medicine, neurological disorders, cardiac repair, and tissue regeneration.

Although promising, lineage conversion therapies raise concerns regarding cellular identity, unintended differentiation, tumour formation, immune reactions, manufacturing consistency, and long-term safety. Their regulation requires scientific validation, clinical-trial authorisation, ethical oversight, and post-treatment monitoring. Indian law does not yet provide a separate comprehensive statutory code exclusively for lineage conversion therapies; applicable drug, biological-product, clinical-trial, and cell-therapy requirements must therefore be examined.

1. LEGAL AND REGULATORY FRAMEWORK IN INDIA

A. DRUGS AND COSMETICS ACT, 1940

The Act and applicable Drugs Rules regulate relevant drugs and biological products. Depending on their characteristics and intended use, lineage-converted cellular products may fall within the regulatory framework for cell-based products or new drugs. The applicable classification must be determined by the competent authority.

B. NEW DRUGS AND CLINICAL TRIALS RULES, 2019

These Rules govern applicable clinical trials, regulatory permissions, ethics oversight, and requirements for new drugs. Experimental cellular interventions must not be marketed as established treatment merely because preliminary laboratory findings appear promising.

C. NATIONAL GUIDELINES FOR STEM CELL RESEARCH, 2017

The guidelines issued jointly by the Indian Council of Medical Research and the Department of Biotechnology provide important standards for stem-cell research, ethical review, and clinical translation. Their precise application to a lineage-converted product depends on the cells, manufacturing process, and applicable statutory classification.

D. REGULATORY DEVELOPMENTS IN 2026

India's regulatory framework for advanced cell and gene therapies has been strengthened through amendments to the Drugs Rules, 1945, and judicial clarification of stem-cell therapy requirements. Developers should verify the current licensing pathway and competent authority before commencing clinical development.

2. PRINCIPAL REGULATORY REQUIREMENTS

A. PRECLINICAL VALIDATION: Developers should demonstrate cellular identity, functional stability, purity, potency, and reproducibility, while assessing unintended cell types and genetic abnormalities.

B. CLINICAL AUTHORISATION: Applicable regulatory permissions and ethics-committee approval must be obtained before clinical trials begin.

C. MANUFACTURING QUALITY: Facilities should comply with applicable good manufacturing practices, maintain traceability of cellular material, and establish validated release criteria.

D. INFORMED CONSENT: Participants must receive understandable information about experimental status, uncertain benefits, potential harms, alternatives, and compensation where legally required.

E. LONG-TERM MONITORING: Follow-up should assess treatment durability, abnormal tissue growth, immune reactions, and delayed adverse effects.

3. RELEVANT CASE LAWS

1. Yash Charitable Trust v. Union of India, 2026 INSC 96

Authority: Direct on stem-cell therapy regulation; analogous to lineage conversion. The Supreme Court held that stem-cell treatment for autism spectrum disorder could not be offered as routine clinical care outside an approved and monitored research or clinical-trial setting. The judgment reinforces the distinction between experimental interventions and established treatment.

2. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

Authority: Direct on medical consent; analogous to experimental cellular treatment. The Supreme Court explained the requirements of valid informed consent. Patients must understand the nature and purpose of a proposed intervention and agree voluntarily.

3. Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651

Authority: Direct on medical-service accountability. The Supreme Court clarified the application of consumer-protection law to medical services, subject to the principles and exceptions explained in the judgment. The case supports accountability where regulated medical services cause legally actionable harm.

4. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1

Authority: Direct on medical negligence principles. The Supreme Court discussed the standard for establishing criminal medical negligence. The judgment is relevant when evaluating professional conduct involving experimental treatments, although liability depends on the evidence and applicable legal standard.

5. Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647

Authority: Analogous. The Supreme Court recognised the precautionary principle and polluter-pays principle in environmental law. The precautionary approach provides a useful analogy for evaluating uncertain biological risks, but the case does not establish a clinical-approval test.

6. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1

Authority: Direct on constitutional privacy; analogous to cellular research. The Supreme Court recognised privacy as a fundamental right. The judgment supports safeguards for participants' genetic information, biological samples, and associated personal data.

4. PRACTICAL COMPLIANCE MEASURES

Developers should document the conversion method, establish validated quality-control procedures, obtain required permissions, maintain independent ethics oversight, and implement adverse-event reporting. Sponsors should also maintain traceability of cellular materials and avoid promotional claims unsupported by clinical evidence.

CONCLUSION

Lineage conversion therapies may expand regenerative medicine, but clinical adoption requires reliable evidence of safety, quality, and effectiveness. Indian drug and clinical-trial legislation, ethical guidelines, and judicial principles provide a framework for responsible development. The cited cases establish relevant principles of consent, accountability, privacy, and precaution; none should be misrepresented as directly deciding the legality of lineage conversion technology itself.